Efficacy and Safety of De Novo Extended-Release Tacrolimus Weight-Based Dosing in Obese vs. Non-Obese Kidney Transplant Recipients
Year: 2025
Type: article
Abstract: Purpose: Tacrolimus is commonly utilized in maintenance immunosuppression in solid organ transplant recipients. Tacrolimus has a narrow therapeutic index and exhibits pharmacokinetic and pharmacodynamic variability. Tacrolimus XR utilizes MeltDose technology, improving water solubility and bioavailability. This formulation provides rapid attainment of therapeutic systemic exposure with less fluctuations in drug levels. The recommended de novo dosing in kidney transplant recipients is based on body weight, however data surrounding optimal dosing in patients with obesity is limited.
Authors: J. Quenzer, A. Diamond, K. Ly, S. Constantinescu, S. Karhadkar, A. Di Carlo, K. Zorbas, K. Chavin
Institutions: Temple University Hospital, Temple University
Language: English
Subfield: Transplantation
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,300
OpenAlex ID: W4412865586